-
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) [Elektronski vir] : a retrospective analysis from an early access programIllini, Oliver ...Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. ... Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.Vir: Therapeutic advances in medical oncology. - ISSN 1758-8359 (Vol. 14, Jan./Dec. 2022, str. 1-22)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2022Jezik - angleškiCOBISS.SI-ID - 112187139
Avtor
Illini, Oliver |
Fabikan, Hannah |
Swalduz, Aurélie |
Vikström, Anders |
Krenbek, Dagmar |
Schumacher, Michael, (medicina) |
Dudnik, Elizabeth |
Studnicka, Michael |
Öhman, Ronny |
Wurm, Robert |
Čufer, Tanja, 1955- |
Mohorčič, Katja, 1978- |
Hochmair, Maximilian J
Teme
Carcinoma, non-small cell lung |
Drug therapy |
Genetics |
Molecular targeted therapy |
Nedrobnocelični karcinom pljuč |
Terapija z zdravili |
Genetika |
Molekularna tarčna terapija |
podatki iz resničnega življenja |
capmatinib |
tarčna terapija |
real-world data |
capmatinib |
targeted therapy
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Illini, Oliver | |
Fabikan, Hannah | |
Swalduz, Aurélie | |
Vikström, Anders | |
Krenbek, Dagmar | |
Schumacher, Michael, (medicina) | |
Dudnik, Elizabeth | |
Studnicka, Michael | |
Öhman, Ronny | |
Wurm, Robert | |
Čufer, Tanja, 1955- | 12179 |
Mohorčič, Katja, 1978- | 30985 |
Hochmair, Maximilian J |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.